Decline in deaths from AIDS due to new antiretrovirals [2]

Lancet

Volumn 349, Issue 9061, 1997, Pages 1294-

  Hogg, Robert S ^b   O'Shaughnessy, Michael V ^b   Gataric, Nada ^b   Yip, Benita ^b   Craib, Kevin ^b   Schechter, Martin T ^b   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFICACY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0343742642     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62505-6     Document Type: Article

References (2)

1. Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions. Vancouver: BC Centre for Excellence in HIV/AIDS, 1996.
2. Montaner JSG, Hogg RS, Yip B, Qataric N, Schechter MT, O'Shaughnessy MV. Zidovudine use rebounds as a result of Lamivudine availability. JAMA 1996; 275: 598.